Suppr超能文献

血清肌酐/胱抑素C比值是胃肠道间质瘤患者肌肉减少症的一个全身性标志物。

Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours.

作者信息

Ding Ping'an, Guo Honghai, Sun Chenyu, Chen Shuya, Yang Peigang, Tian Yuan, Lowe Scott, Zhao Qun

机构信息

The Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Hebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer, Shijiazhuang, China.

出版信息

Front Nutr. 2022 Sep 2;9:963265. doi: 10.3389/fnut.2022.963265. eCollection 2022.

Abstract

BACKGROUND

It is well known that sarcopenia is a common risk factor in patients with gastrointestinal tumours, which may negatively affect the clinical outcome and prognosis. Recent studies suggest that serum creatinine-cystatin C (Cr/CysC) ratio may be associated with sarcopenia, but this association lacks sufficient evidence in patients with gastrointestinal stromal tumours (GIST). Therefore, this study aimed to investigate whether the Cr/CysC ratio was associated with sarcopenia and recurrence-free survival (RFS) in patients with GIST.

MATERIALS AND METHODS

The study retrospectively analysed 413 patients with GIST who underwent surgical resection from January 2016 to January 2020. The serum Cr/CysC ratio was determined as a proxy for sarcopenia by comparing it with various biomarkers and Cox multifactorial analysis was used to determine the relationship between Cr/CysC ratio and prognosis.

RESULTS

Serum Cr/CysC was positively correlated with skeletal muscle area (SMA) ( = 0.256, < 0.001), skeletal muscle index (SMI) ( = 0.300, < 0.001), and hand grip strength (HGS) ( = 0.251, < 0.001). The area under the receiver operator characteristic curve for sarcopenic subjects with serum Cr/CysC ratio was significantly greater than other biomarkers (Cr/CysC: 0.840, CysC: 0.732, Cr: 0.518). The optimal cut-off value for Cr/CysC was 0.65, and patients in the high Cr/CysC group had a higher 3-year recurrence-free survival (RFS) than those in the low Cr/CysC group (92.72 vs. 72.46%, < 0.001). Cox multifactorial analysis found that the Cr/CysC ratio was an independent risk factor for RFS in GIST patients (HR = 2.143, 95% CI: 1.431-5.459, = 0.011).

CONCLUSION

Serum Cr/CysC ratio has satisfactory and comparable diagnostic accuracy, and prognostic value for sarcopenia in patients with GIST. Therefore, it can be a simple and practical clinical tool to screen sarcopenia in GIST patients. However, further studies are required to validate these findings.

摘要

背景

众所周知,肌肉减少症是胃肠道肿瘤患者的常见危险因素,可能对临床结局和预后产生负面影响。最近的研究表明,血清肌酐-胱抑素C(Cr/CysC)比值可能与肌肉减少症有关,但在胃肠道间质瘤(GIST)患者中这种关联缺乏充分证据。因此,本研究旨在调查Cr/CysC比值是否与GIST患者的肌肉减少症及无复发生存期(RFS)相关。

材料与方法

本研究回顾性分析了2016年1月至2020年1月期间接受手术切除的413例GIST患者。通过将血清Cr/CysC比值与各种生物标志物进行比较,将其确定为肌肉减少症的替代指标,并采用Cox多因素分析来确定Cr/CysC比值与预后之间的关系。

结果

血清Cr/CysC与骨骼肌面积(SMA)(r = 0.256,P < 0.001)、骨骼肌指数(SMI)(r = 0.300,P < 0.001)和握力(HGS)(r = 0.251,P < 0.001)呈正相关。血清Cr/CysC比值用于诊断肌肉减少症患者的受试者工作特征曲线下面积显著大于其他生物标志物(Cr/CysC:0.840,CysC:0.732,Cr:0.518)。Cr/CysC的最佳截断值为0.65,高Cr/CysC组患者的3年无复发生存率(RFS)高于低Cr/CysC组(92.72%对72.46%,P < 0.001)。Cox多因素分析发现,Cr/CysC比值是GIST患者RFS的独立危险因素(HR = 2.143,95%CI:1.431 - 5.459,P = 0.011)。

结论

血清Cr/CysC比值对GIST患者的肌肉减少症具有令人满意且可比的诊断准确性和预后价值。因此,它可以作为一种简单实用的临床工具来筛查GIST患者的肌肉减少症。然而,需要进一步研究来验证这些发现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3368/9478187/f8b37408eaa6/fnut-09-963265-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验